Beractant

DEA Class;  Rx

Common Brand Names; Survanta

Bovine-derived lung surfactant; administered intratracheally; used to prevent and treat neonatal RDS.

Orphan designation of aerosolized beractant for treatment of respiratory distress syndrome

For neonatal respiratory distress syndrome prophylaxis in premature neonates and for the treatment of neonatal respiratory distress syndrome (RDS).

For the treatment of acute respiratory distress syndrome (ARDS). Intratracheal dosage (Survanta) Adults

• Transient bradycardia (12%)
• O2 desaturation (10%)
• Apnea
• Endotracheal tube blockage
• Endotracheal tube reflux
• Hypotension
• Hypercarbia
• Hypertension/hypotension
• Sepsis
• Vasoconstriction

For endotracheal administration only

Rales, moist breathing sounds may occur normally with administration

Infant may exhibit bradycardia & cyanosis

Do not chill & thaw more than once; single use vials

Lung oxygenation may improve rapidly, which in turn will require adjustments in oxygen delivery and ventilator settings

Administer only in a highly-supervised clinical setting with immediate availability of clinicians experienced in intubation and ventilatory management of premature infants

Pregnancy Category: Not applicable

Lactation: Not applicable

Adults

Safe and effective use has not been established; doses of 100 mg/kg have been reported for off-label use in the treatment of acute respiratory distress syndrome (ARDS).

Geriatric

Safety and efficacy have not been established.

Adolescents

Safety and efficacy have not been established.

Children

Safety and efficacy have not been established.

Infants

> 1 month: Safety and efficacy have not been established.

Neonates

100 mg/kg birth weight (4 mL/kg birth weight)/dose intratracheally.

Sparfloxacin 

Intratracheal suspension

• 25mg/mL